Company

GATT Technologies (BV, Nijmegen, The Netherlands) is a privately owned, clinical-stage, medical device company. GATT has developed a synthetic platform leveraging an activated polymer technology that aims to become the next frontier in managing complex bleeding and sealing. GATT’s hemostats and sealants focus on controlling severe and/or problematic surgical bleedings as well as preventing and treating organ leakages. GATT’s solutions have the potential to become a superior alternative to the current fibrin and PEG-polymer based solutions in terms of speed, efficacy and cost.

The current focus of the company is to conduct its first clinical trial in Europe for its lead product – GATT-Patch – a fast hemostatic sealing patch. Following the European trial, additional trials will be executed – in the US, to target FDA approval, as well as to expand its target indications such as soft tissue, cardiovascular, lung, kidney and pancreas. Additionally, the company is advancing its other products including GATT-Powder (targeted for use on large surfaces and hard to access areas) and GATT-Gel (targeted for high pressure vessel sealing).

Gatt Technologies

Transistorweg 5

6534 AT Nijmegen

info@gatt-tech.com

https://www.gatt-tech.com/ 

More companies in this area

Khondrion

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting primary mitochondrial disease.

Staten Biotechnology

Staten Biotechnology aims to develop novel and innovative strategies for the prevention of cardiovascular events, the largest unmet medical need in dyslipidemia.

SPL Medical

SPL Medical is strongly committed to improve MRI imaging to enable a much more precise, effective and patient friendly diagnosis of cancer metastasis.

QM Diagnostics

QM Diagnostics is an internationally operating, independent and innovative diagnostic microbiological laboratory.

We are specialized in health monitoring of small laboratory animals used for biomedical research.

Cardiacbooster

Developing the next generation of percutaneous left ventricular assist devices.

ATRO Medical

ATRO Medical is working hard on the transition to the clinic and the first implantation of a Trammpolin™ meniscus prosthesis in the patient is expected in 2020.

Settle at Novio Tech Campus!

Connect with Novio Tech Campus!